Fresenius Kabi, an operating company of Fresenius, announced that Epinephrine Injection, USP, is now available in the U.S. in 30 mg per 30 mL multi-dose vials.
Epinephrine Injection 30 mg per 30 mL is a prescription medicine used for emergency treatment of allergic reactions (Type 1), including anaphylaxis, in adults and pediatric patients and to increase mean arterial blood pressure in adult patients with hypotension associated with septic shock.
The product launch adds to the company’s offerings of Epinephrine Injection. In December 2024, Fresenius Kabi introduced the first generic version of Epinephrine, USP, in a 1 mg per mL vial for U.S. customers.
“We are pleased to offer our customers a cost-effective solution that supports quality patient care,” said Arun Verma, president, Fresenius Kabi Region U.S. and Member of the Executive Leadership Team, Fresenius Kabi AG. “At Fresenius Kabi, we are continually striving for new solutions as a trusted partner with the healthcare community.”
Epinephrine Injection is manufactured in the U.S., reflecting the company’s commitment to domestic production. Since 2017, Fresenius Kabi has invested nearly $1 billion to expand and modernize advanced U.S. pharmaceutical production and distribution facilities. More than 70% of the units shipped by Fresenius Kabi in the U.S. are drugs listed on the FDA’s Essential Medicines List.
